Zentalis clinical hold resolution came ‘no strings attached,’ says Oppenheimer

After Zentalis announced resolution of azenosertib’s partial clinical hold, Oppenheimer said the firm was “delighted” that the resolution came “no strings attached,” meaning with no risk mitigation strategies, changes to the protocol, or eligibility being required by the FDA. This fact, combined with the speed of the resolution of about months, suggests that the hold was “simply a procedural requirement by the FDA,” argues the analyst, who thinks the drug’s safety still compares nicely to other treatments for gynecological cancers. The firm reiterates an Outperform rating and $20 price target on shares of Zentalis, which are up 88c, or 27%, to $4.12 in Monday morning trading.